Free Declaration - District Court of Delaware - Delaware

Case 1:07-cv-00156-JJF

Document 94

Filed 05/14/2008

Page 1 of 3

Case 1:07-cv-00156-JJF

Document 94

Filed 05/14/2008

Page 2 of 3

Case 1:07-cv-00156-JJF

Document 94

Filed 05/14/2008

Page 3 of 3

CERTIFICATE OF SERVICE I, the undersigned, hereby certify that on May 14, 2008, I electronically filed the foregoing with the Clerk of the Court using CM/ECF, which will send notification of such filing(s) to the following: Josy W. Ingersoll I also certify that copies were caused to be served on May 14, 2008, upon the following in the manner indicated: BY HAND Josy W. Ingersoll Andrew A. Lundgren Young, Conaway, Stargatt & Taylor, LLP The Brandywine Building 1000 West Street, 17th Flr. Wilmington, DE 19801 BY EMAIL Gerald J. Flattmann, Jr. Christine Willgoos Gregory A. Morris Kirkland & Ellis 153 East 53rd Street New York, NY 10022-4611

/s/Karen Jacobs Louden ___________________________ Karen Jacobs Louden (#2881)

Case 1:07-cv-00156-JJF

Document 94-2

Filed 05/14/2008

Page 1 of 8

Exhibit 1

Case 1:07-cv-00156-JJF

Document 94-2

Filed 05/14/2008

Page 2 of 8
AUSTIN BOSTON
BRUSSELS BUDAPEST DALLAS FRANKFURT

WEll, GOTSHAl& MANGES LLP
SILICON VALLEY OFFICE

201 REDWOOD SHORES PARKWAY

REDWOOD SHORES, CALIFORNIA 94065

(650) 802-3000 FAX: (650) 802-3100

HOUSTON LONDON
MIAMI

MUNICH

NEW YORK
PARIS PRAGUE PROVIDENCE SHANGHAI SINGAPORE WARSAW WASHINGTON, D.C.

VERNON M. WINTERS
DIRECT LINE (650) 802-3005 E-MAIL: vern.winters(gweil.com

Februar 27, 2008

VI

EMAI

Gerald Flattman, Esq.

Kirkland & Ellis LLP 153 E. 53rd Street New York, NY 10022-461 1 GFlattmannØ)kirkland. com

Re: PDL BioPharma, Inc. v. Alexion Pharmaceuticals, Inc. D. Del. Case No. 07-156
Dear Gerald:

Plaintiff, PDL BioPhara, Inc., provides the following list of claim term or phrases for, absent agreement by the paries, construction by the Court with respect to the asserted claim ofPDL's U.S. Patents Nos. 5,693,761,5,693,762, and 6,180,370.
PDL's investigation is ongoing and the defendant, Alexion

Pharmaceuticals, Inc., has not yet disclosed to PDL its list of term and claim elements

for construction. In addition, and in violation of an agreement between the paries,
defendant has failed to identify with any sort of reasonable specificity its invalidity contentions. Accordingly, PDL reserves its right to supplement, amend, or modify this disclosure.
1. "acceptor immunoglobulin";
2. "complementarity determning regions (CDRs) from a (the) donor

immunoglobulin" ;

(#289548)

Case 1:07-cv-00156-JJF
WEll, GOTSHAl & MANGES llP

Document 94-2

Filed 05/14/2008

Page 3 of 8

Gerald Flattmann, Esq.

Februar 27,2008
Page 2

3. "donor immunoglobulin";
4. "variable region framework"; and
5. "is at least 65% (70%) identical to the (sequence of the) donor

imunoglobulin heavy (light) chain variable region framework."

cc: Josy Ingersoll, Esq. (via email) Karen Jacobs Louden, Esq. (via email) Wendy Adam (via email)

(JlngersollØ)ycst.com) (KLoudenØ)NAT.com) (WAdamØ)kikland.com)

(#289548)

Case 1:07-cv-00156-JJF

Document 94-2

Filed 05/14/2008

Page 4 of 8

Exhibit 2

Case 1:07-cv-00156-JJF

Document 94-2

Filed 05/14/2008

Page 5 of 8

KIRKLAND 8. ELLIS LLP
AND AFFILIATED PARTNERSHIPS

Christine Willgoos To Call Writer Directly: 212 446-4964 [email protected]

Citigroup Center 153 East 53rd Street New York, New York 10022-4611 Facsimile: 212 446-4900 www. kirkland.com

February 27,2008 VIA E-MAIL Eric Xanthopoulos Weil, Gotshal & Manges LLP Silicon Valley Office 20 1 Redwood Shores Parkway Redwood Shores, CA 94065 Re: PDL Biopharma, Inc. v. Alexion Pharmaceuticals, Inc. Dear Eric: As per the stipulation agreed by the parties and entered by the Court, below please find Alexion's tentative proposed claim terms for construction by the Court. Alexion reserves the right to modify the claim terms proposed for construction. In addition, Alexion reserves the right to propose constructions for any claim terms for which PDL requests construction. Alexion's Progosed Terms For Construction
1.

First and second polynucleotides respectively encoding heavy and light chain variable regions of a humanized immunoglobulin humanized immunoglobulin humanized immunoglobulin heavy and light chains complementarity determining regions (CDRs) donor immunoglobulin heavy and light chain variable region frameworks / heavy and light chain frameworks human acceptor immunoglobulin / acceptor human immunoglobulin variable region framework region / framework / variable region framework sequence of the humanized immunoglobulin heavy chain variable framework region humanized immunoglobulin heavy chain variable region framework

2.
3.

4. 5. 6. 7. 8. 9. 10. 11.

Chicago

London

Los Angeles

Munich

San Francisco

Washington, D.C.

Case 1:07-cv-00156-JJF

Document 94-2

Filed 05/14/2008

Page 6 of 8

Eric Xanthopoulos February 27,2008 Page 2

KIRKLAND 8. ELLIS LLP

humanized immunoglobulin light chain variable region framework sequence of the humanized immunoglobulin light chain variable framework region outside the Kabat and Chothia CDRs DNA segment encoding a humanized heavy chain variable region / DNA segment encoding the humanized immunoglobulin heavy chain variable region DNA segment encoding a humanized light chain variable region / DNA segment encoding the humanized immunoglobulin light chain variable region DNA segments encoding the humanized heavy and light chains DNA segments encoding humanized light and heavy chain variable regions / DNA segments encoding heavy and light chain variable regions of a humanized immunoglobulin hypervariable regions outside the hypervariable regions Kabat CDRs outside the Kabat CDRs Chothia CDR H1 outside the Chothia CDR H1 (amino acids 26-32) Sincerely,

Christine Willgoos

u

Case 1:07-cv-00156-JJF

Document 94-2

Filed 05/14/2008

Page 7 of 8

Exhibit 3

Case 1:07-cv-00156-JJF

Document 94-2

Filed 05/14/2008

Page 8 of 8

----- Original Message ----From: "Christine Willgoos" [[email protected]] Sent: 05/05/2008 10:04 AM AST To: Jennifer Wu Cc: [email protected] Subject: Re: PDL/Alexion

Jennifer: Further to Alexion's February 27, 2008 letter regarding claim terms for construction, Alexion intends to pursue contructions regarding terms 1, 2, 4-7, 9, 11-12 and 15-19 as identified in that letter. In addition, Alexion will ask the Court to construe the term: "synthesizing a [the] DNA segment encoding a humanized heavy [light] chain variable region." Regards, Christine

[email protected] 05/01/2008 04:30 PM To [email protected] cc [email protected] Subject PDL/Alexion

Christine, Given that Alexion has proposed the term "human acceptor immunoglobulin / acceptor human immunoglobulin" for construction, it is not necessary for the Court to construe PDL's proposed term "acceptor immunoglobulin." We agree with Alexion's proposal that Court should construe "human acceptor immunoglobulin / acceptor human immunoglobulin," and will exchange constructions on those terms as Alexion has proposed. Regards, Jennifer Jennifer H. Wu Weil, Gotshal & Manges LLP